Detail akcie Newron Pharma online

Business Summary: Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Newron Pharmaceuticals SpA revenues increased 49% to EUR9.1M. Net loss decreased 7% to EUR16.2M. Revenues reflect Other Rev from BiS Related ACT increase from EUR144K to EUR2.3M, Royalties from contracts with customers increase of 13% to EUR6.7M, Licence income from contracts with custo increase from EUR14K to EUR58K. Lower net loss reflects Staff cost decrease of 7% to EUR3.2M (expense).